Journal Article10.1080/00498250802017715
A regulatory viewpoint on transporter-based drug interactions.
186
TL;DR: A regulatory viewpoint on transporters and their potential role in drug–drug interactions is provided and criteria that may warrant conduct of in vivo P-gp-mediated drug interaction studies based on in vitro assessment are explained.
read more
Abstract: 1. Pharmacokinetic drug interactions can lead to serious adverse events and the evaluation of a new molecular entity's (NME) drug-drug interaction potential is an integral part of drug development and regulatory review before its market approval. Clinically relevant interactions mediated by transporters are of increasing interest in clinical development and research in this emerging area and it has been revealed that drug transporters can play an important role in modulating drug absorption, distribution, metabolism and elimination. 2. Acting alone or in concert with drug-metabolizing enzymes transporters can affect the pharmacokinetics and/or pharmacodynamics of a drug. The newly released drug interaction guidance by the US Food and Drug Administration (USFDA) includes new information addressing drug transporter interactions with a primary focus on P-glycoprotein (P-gp, ABCB1). 3. This paper provides a regulatory viewpoint on transporters and their potential role in drug-drug interactions. It first outlines information that might be needed during drug development and ultimately included in new drug application (NDA) submissions to address potential transporter-mediated drug interactions. Next, it explains criteria that may warrant conduct of in vivo P-gp-mediated drug interaction studies based on in vitro assessment. In addition, it includes a review case that describes the evaluation of data suggesting a P-gp-based induction interaction.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.
Barbara Döring,Ernst Petzinger +1 more
TL;DR: This review deals with the function of drug carriers in various organs and their impact on drug metabolism and elimination.
122
Drug interaction potential of resveratrol
TL;DR: It is concluded that resveratrol may lead to interactions with various CYPs, especially when taken in high doses, and patients who ingest high doses of this food supplement combined with additional medications may be at risk of experiencing clinically relevant drug-drug interactions.
121
Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions
TL;DR: The current review provides an assessment of the contribution of intestinal inhibition and induction in conjunction with different perpetrator and victim drug-related properties, focusing in particular on victim drugs with high intestinal first-pass extraction.
120
Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions
TL;DR: A comprehensive review of P-glycoprotein-mediated DDIs is conducted and a classification for individual drugs based on both in vitro and in vivo evidence (substrates, inhibitors and inducers) is suggested.
102
2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
TL;DR: The new 2020 clinical DDI guidance from the FDA now has even higher harmonization with the guidances (or guidelines) from the EMA and PMDA.
95
References
Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
Chi-Yuan Wu,Leslie Z. Benet +1 more
TL;DR: It is suggested that a Biopharmaceutics Drug Disposition Classification System (BDDCS) using elimination criteria may expand the number of Class 1 drugs eligible for a waiver of in vivo bioequivalence studies and provide predictability of drug disposition profiles for Classes 2, 3, and 4 compounds.
1.4K
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
TL;DR: It is shown here that the drugs loperamide, domperidone, and ondansetron are transported substrates for the mouse mdr1a P-GP and its human homologue MDR1, and the possible role that the drug-transporting P- GP(s) may play in the clinical use of many drugs, especially those with potential targets in the central nervous system.
P-glycoprotein: from genomics to mechanism
TL;DR: A model for how ATP energizes transfer of substrates from these binding sites on P-gp to the outside of the cell is proposed, which accounts for the apparent stoichiometry of two ATPs hydrolysed per molecule of drug transported.
1.1K
Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System
Michael Levin
- 12 Dec 2001
TL;DR: This draft guidance is intended to provide a guide to the administration's planned implementation of e-cigarettes in the United States and to help states and local authorities better understand the risks and benefits of these products.
940
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.
TL;DR: Intestinal P-glycoprotein, which is encoded by the MDR1 gene, plays an important role in the absorption and presystemic elimination of many xenobiotics, and its induction is mediated by a DR4 motif in the upstream enhancer at about −8 kilobase pairs, to which PXR binds.
919
Related Papers (5)
Kathleen M. Giacomini,Shiew-Mei Huang,Donald J. Tweedie,Leslie Z. Benet,Kim L. R. Brouwer,Xiaoyan Chu,Amber Dahlin,Raymond Evers,Volker Fischer,Kathleen M. Hillgren,Keith Hoffmaster,Toshihisa Ishikawa,Dietrich Keppler,Richard B. Kim,Caroline A. Lee,Mikko Niemi,Joseph W. Polli,Yuicchi Sugiyama,Peter W. Swaan,Joseph A. Ware,Stephen H. Wright,Sook Wah Yee,Maciej J. Zamek-Gliszczynski,Lei Zhang +23 more